557.80

3.76% 20.22

Idexx Laboratories Inc (IDXX)

Overview News Price History Option Chain Financials Why IDXX Down? Discussions Forecast Stock Split

Idexx Laboratories Inc stock is traded at $557.80, with a volume of 813.54K. It is up +3.76% in the last 24 hours and up +1.27% over the past month. Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.

Previous Close:

$537.58

Open:

$543.71

24h Volume:

813.54K

Relative Volume:

1.31

Market Cap:

$44.00B

Revenue:

$4.45B

Net Income/Loss:

$1.10B

P/E Ratio:

41.04

EPS:

13.591

Net Cash Flow:

$1.06B

1W Performance:

+0.52%

1M Performance:

+1.27%

6M Performance:

-16.75%

1Y Performance:

+2.78%

1-Day Range:

$538.87

$559.91

1-Week Range:

$518.55

$561.15

52-Week Range:

$506.91

$769.98

Idexx Laboratories Inc Stock (IDXX) Company Profile

Name

Idexx Laboratories Inc

Sector

Healthcare (1098)

Industry

Diagnostics & Research (48)

Phone

(207) 556-0300

Address

ONE IDEXX DRIVE, WESTBROOK, ME

Employee

11,000

Twitter

@idexx

Next Earnings Date

2026-08-03

Latest SEC Filings

IDXX's Discussions on Twitter

Compare IDXX vs TMO, DHR, NTRA, WAT

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IDXX Idexx Laboratories Inc	557.80	41.53B	4.45B	1.10B	1.06B	13.59
TMO Thermo Fisher Scientific Inc	523.44	186.32B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	197.93	134.82B	24.78B	3.68B	5.29B	5.1743
NTRA Natera Inc	279.32	38.88B	2.50B	-226.32M	71.51M	-1.6412
WAT Waters Corp	379.29	36.82B	3.77B	449.25M	240.68M	7.8556

Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-15-26	Initiated	Citigroup	Neutral
Dec-09-25	Initiated	Barclays	Overweight
Oct-31-25	Upgrade	Stifel	Hold → Buy
Oct-01-25	Initiated	UBS	Neutral
Aug-05-25	Reiterated	BTIG Research	Buy
Jul-01-25	Initiated	Jefferies	Buy
Dec-02-24	Initiated	Leerink Partners	Outperform
Jul-25-24	Initiated	BTIG Research	Buy
Jan-30-24	Downgrade	Piper Sandler	Overweight → Neutral
Dec-07-23	Initiated	Exane BNP Paribas	Outperform
Dec-04-23	Upgrade	Cleveland Research	Neutral → Buy
Aug-02-23	Downgrade	Atlantic Equities	Overweight → Neutral
Jul-25-22	Downgrade	Stifel	Buy → Hold
Jul-21-22	Upgrade	Goldman	Neutral → Buy
Jul-12-22	Initiated	Piper Sandler	Overweight
May-05-22	Downgrade	BofA Securities	Buy → Neutral
Feb-08-22	Initiated	Atlantic Equities	Overweight
Nov-18-21	Initiated	Morgan Stanley	Overweight
Aug-05-21	Resumed	Credit Suisse	Outperform
Jul-12-21	Downgrade	Guggenheim	Buy → Neutral
Feb-17-21	Initiated	Barclays	Overweight
Sep-09-19	Initiated	Goldman	Neutral
May-23-19	Initiated	Guggenheim	Buy
Nov-02-18	Reiterated	BofA/Merrill	Buy
May-07-18	Reiterated	Stifel	Buy
Jan-16-18	Initiated	Piper Jaffray	Overweight
Aug-23-17	Upgrade	BofA/Merrill	Neutral → Buy
Jul-28-17	Upgrade	CL King	Neutral → Buy
Feb-03-17	Downgrade	Feltl & Co.	Hold → Sell
Sep-29-16	Resumed	BofA/Merrill	Neutral
Aug-16-16	Reiterated	Stifel	Buy
Aug-03-16	Upgrade	Northcoast	Sell → Neutral
Jul-20-16	Reiterated	Canaccord Genuity	Buy
Apr-19-16	Reiterated	Canaccord Genuity	Buy
Apr-01-16	Initiated	CL King	Neutral
Mar-21-16	Reiterated	Stifel	Buy
Feb-04-16	Initiated	Credit Suisse	Outperform
Oct-29-15	Reiterated	Stifel	Buy
Aug-28-15	Downgrade	Raymond James	Outperform → Mkt Perform
Aug-13-15	Reiterated	Stifel	Buy
Jul-23-15	Reiterated	Canaccord Genuity	Buy

View All

Idexx Laboratories Inc Stock (IDXX) Latest News

Jul 01, 2026

IDEXX Laboratories to Release 2026 Second Quarter Financial Results - Business Wire

Jul 01, 2026

Jun 29, 2026

IDEXX Laboratories Inc. stock underperforms Monday when compared to competitors - MarketWatch

Jun 29, 2026

IDEXX Laboratories, Inc.(NasdaqGS: IDXX) added to Russell Midcap Value Benchmark - marketscreener.com

Jun 29, 2026

Is the Options Market Predicting a Spike in IDEXX Laboratories Stock? - Zacks Investment Research

Jun 29, 2026

Is IDEXX Laboratories stock underperforming the Nasdaq? - MSN

Jun 29, 2026

IDEXX Laboratories (IDXX) Stock Analysis: Uncovering a Potential 28.58% Upside for Investors - DirectorsTalk Interviews

Jun 29, 2026

IDEXX Laboratories with a clear strategy focus, shares anchored in the NASDAQ-100 - AD HOC NEWS

Jun 29, 2026

IDEXX Laboratories, Inc.(NasdaqGS: IDXX) added to Russell 1000 Value Benchmark - marketscreener.com

Jun 29, 2026

Jun 28, 2026

The Catalyst Dx from IDEXX Laboratories Inc.compact chemistry analyzer for fast in-clinic results - AD HOC NEWS

Jun 28, 2026

IDEXX Laboratories, Inc.(NasdaqGS: IDXX) added to Russell 3000 Value Benchmark - marketscreener.com

Jun 28, 2026

IDEXX Laboratories opens the week with a clear consensus, NASDAQ-100 shares in a steady trend - Ad-hoc-news.de

Jun 28, 2026

Jun 27, 2026

IDEXX Laboratories focuses on long-term growth, shares in NASDAQ-100 healthcare peer group - Ad-hoc-news.de

Jun 27, 2026

Jun 26, 2026

New diagnostic test for kidney injury - DVM360

Jun 26, 2026

IDEXX Laboratories opens the week with earnings focus, shares steady - Ad-hoc-news.de

Jun 26, 2026

Jun 25, 2026

IDEXX Laboratories sets the pace with raised 2026 guidance, analysts back the stock - Ad-hoc-news.de

Jun 25, 2026

Enterprise value to EBITDA forward of IDEXX Laboratories, Inc. – DUS:IX1 - TradingView

Jun 25, 2026

Why IDEXX Laboratories Stock Looks Undervalued After Raising Its 2026 EPS Outlook to $15 - TIKR.com

Jun 25, 2026

Are IDEXX Laboratories’ (IDXX) New SDMA and Tapeworm Tests Deepening Its Diagnostics Moat? - Sahm

Jun 25, 2026